Kyle LaHucik

Articles by Kyle LaHucik

NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand - Endpoints News

Health September 10, 2026

Af­ter tin­ker­ing with the bi­ol­o­gy of the broad­ly ap­peal­ing an­ti-in­flam­ma­to­ry NL­RP3 path­way, NodThera is now plot­ting its piv­otal tri­al plans for 2027.

Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics - Endpoints News

Business July 8, 2026

Ver­tex Phar­ma­ceu­ti­cals is mak­ing the largest ac­qui­si­tion in its his­to­ry, beef­ing up its com­mer­cial port­fo­lio with a $10 bil­lion takeover of Cri­net­ics Phar­ma­ce...

Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B - Endpoints News

Business May 13, 2026

Its be­com­ing Hen­grui Phar­mas world, and some West­ern drug­mak­ers are just liv­ing in it. Chi­nas largest phar­ma com­pa­ny, which boasts one of the biggest pipelines

Exclusive: Mediar gains $76M for clinical trials of three fibrosis drugs - Endpoints News

Health January 8, 2026

A fi­bro­sis biotech has reeled in $76 mil­lion to get clin­i­cal da­ta on three ex­per­i­men­tal med­i­cines over the next two years. Me­di­ar Ther­a­peu­tics raised the